Sight Sciences announces acceptance for publication of GEMINI 2 trial

Sight Sciences announced the acceptance for publication in Clinical Ophthalmology of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI Surgical System technology. Publication is currently expected by December 31, 2023. GEMINI 2, a prospective, multi-center, medication washout trial designed to obtain 36-month follow-up for patients treated in the original 12-month GEMINI trial, has been completed. Favorable results demonstrate sustained and clinically significant intraocular pressur reduction of greater than 20% and clinically significant IOP lowering medication reduction at 36 months. The prospective 3-year clinical outcomes in the GEMINI 2 trial confirm and extend the previously published 12-month data from the original GEMINI trial. GEMINI 2 included 66 patients across eleven participating sites, and all patients underwent medication wash-out at the two-year and three-year endpoints so that the IOP-lowering effect of the OMNI procedure could be better isolated and assessed. GEMINI 2 Clinical Outcomes: Through three years, data from the GEMINI trial and GEMINI 2 study extension reported a 20% or more reduction of IOP in patients on the same or reduced medication at 24 months and at 36 months. Sustained medication reductions at 24 and 36 months were also reported, with 77% of study patients medication-free at two years and 74% of study patients medication-free at three years post-procedure. The published 36-month long-term follow-up data from the GEMINI 2 multi-center trial, along with the published 2-year long-term follow-up data from the ROMEO 2 multi-center study, demonstrate that the beneficial reductions in IOP and medication use observed at the 12-month timepoint with the OMNI procedure were sustained for two and three years post-operatively. The low rate of secondary surgical interventions observed over the study period suggests that patients treated with the OMNI procedure are unlikely to require more aggressive and invasive glaucoma surgery for a meaningful period of time.